Millennium Management’s Gyre Therapeutics GYRE Stock Holding History

Millennium Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-13,333	Closed	-$587K	–	4597
2020 Q2	$587K	Buy	+13,333	New	+$626K	﹤0.01%	3308

Other funds holding GYRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management's GYRE Position: Q4 2025 in Review

Millennium Management sold out of Gyre Therapeutics (GYRE) in Q4 2025, closing a stake of 35,751 shares — an estimated $267K sold.

Millennium Management first reported a position in GYRE in Q2 2013 and held it in 31 quarters. The position peaked at $6.71M in Q2 2020. 44 funds tracked by Wall St. Rank hold GYRE as of Q4 2025.

Millennium Management reported no remaining Gyre Therapeutics position as of Q4 2025 after selling out during the quarter.
Millennium Management sold 35,751 Gyre Therapeutics shares in Q4 2025, an estimated $267K.
Millennium Management first reported a position in Gyre Therapeutics in Q2 2013 and held it in 31 quarters.
Millennium Management's Gyre Therapeutics position peaked at $6.71M in Q2 2020.
44 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2025.

Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.